Concepts (108)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Myositis | 17 | 2024 | 33 | 10.130 |
Why?
|
| Dermatomyositis | 3 | 2024 | 12 | 1.960 |
Why?
|
| Sarcoidosis | 2 | 2020 | 14 | 1.280 |
Why?
|
| Patient Reported Outcome Measures | 4 | 2024 | 501 | 1.080 |
Why?
|
| Rheumatology | 5 | 2024 | 85 | 0.950 |
Why?
|
| Matrix Metalloproteinase 3 | 1 | 2024 | 5 | 0.880 |
Why?
|
| Polymyositis | 1 | 2023 | 8 | 0.870 |
Why?
|
| Humans | 29 | 2024 | 27074 | 0.830 |
Why?
|
| Autoimmune Diseases | 1 | 2024 | 44 | 0.830 |
Why?
|
| Clinical Trials as Topic | 1 | 2024 | 216 | 0.830 |
Why?
|
| Vasculitis, Central Nervous System | 2 | 2020 | 7 | 0.820 |
Why?
|
| Fitness Trackers | 1 | 2022 | 13 | 0.800 |
Why?
|
| Myocarditis | 1 | 2022 | 12 | 0.780 |
Why?
|
| Myasthenia Gravis | 1 | 2022 | 34 | 0.770 |
Why?
|
| Adult | 12 | 2024 | 7831 | 0.740 |
Why?
|
| Muscle Strength | 2 | 2023 | 130 | 0.730 |
Why?
|
| Muscle Weakness | 1 | 2021 | 34 | 0.720 |
Why?
|
| Osteoporosis | 1 | 2022 | 77 | 0.710 |
Why?
|
| Adrenocorticotropic Hormone | 1 | 2020 | 7 | 0.700 |
Why?
|
| Activities of Daily Living | 2 | 2022 | 595 | 0.690 |
Why?
|
| Central Nervous System Diseases | 1 | 2020 | 17 | 0.650 |
Why?
|
| Tattooing | 1 | 2019 | 3 | 0.640 |
Why?
|
| Neoplasms | 1 | 2022 | 237 | 0.640 |
Why?
|
| Microscopic Angioscopy | 1 | 2019 | 1 | 0.640 |
Why?
|
| Capillaries | 1 | 2019 | 11 | 0.640 |
Why?
|
| Microcirculation | 1 | 2019 | 29 | 0.630 |
Why?
|
| Scleroderma, Systemic | 1 | 2019 | 8 | 0.630 |
Why?
|
| Skin Diseases | 1 | 2019 | 25 | 0.620 |
Why?
|
| Receptors, Adrenergic, beta | 1 | 2018 | 8 | 0.590 |
Why?
|
| Leukocytes | 1 | 2018 | 34 | 0.590 |
Why?
|
| Flow Cytometry | 1 | 2018 | 107 | 0.580 |
Why?
|
| Prospective Studies | 5 | 2023 | 1778 | 0.570 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2019 | 190 | 0.510 |
Why?
|
| Exercise | 3 | 2022 | 450 | 0.430 |
Why?
|
| Reproducibility of Results | 4 | 2022 | 676 | 0.400 |
Why?
|
| Female | 10 | 2023 | 15213 | 0.360 |
Why?
|
| Consensus | 3 | 2024 | 87 | 0.310 |
Why?
|
| Male | 9 | 2023 | 14772 | 0.310 |
Why?
|
| Follow-Up Studies | 4 | 2021 | 1792 | 0.300 |
Why?
|
| Fatigue | 2 | 2023 | 57 | 0.260 |
Why?
|
| Pain | 3 | 2023 | 413 | 0.250 |
Why?
|
| Quality of Life | 4 | 2023 | 629 | 0.240 |
Why?
|
| Lymphotoxin-alpha | 1 | 2024 | 3 | 0.220 |
Why?
|
| Global Health | 1 | 2024 | 36 | 0.220 |
Why?
|
| Chemokines | 1 | 2024 | 21 | 0.220 |
Why?
|
| Cross-Sectional Studies | 2 | 2024 | 891 | 0.220 |
Why?
|
| Middle Aged | 6 | 2023 | 8923 | 0.210 |
Why?
|
| Research Design | 1 | 2024 | 185 | 0.200 |
Why?
|
| Cytokines | 1 | 2024 | 222 | 0.200 |
Why?
|
| Monitoring, Ambulatory | 1 | 2022 | 19 | 0.200 |
Why?
|
| Muscles | 1 | 2022 | 58 | 0.190 |
Why?
|
| Physicians | 1 | 2023 | 122 | 0.190 |
Why?
|
| Glucocorticoids | 1 | 2022 | 68 | 0.190 |
Why?
|
| Muscle Strength Dynamometer | 1 | 2021 | 17 | 0.180 |
Why?
|
| Monitoring, Physiologic | 1 | 2021 | 68 | 0.180 |
Why?
|
| Information Systems | 1 | 2021 | 24 | 0.180 |
Why?
|
| Attitude to Health | 1 | 2021 | 99 | 0.180 |
Why?
|
| Biomarkers | 1 | 2024 | 562 | 0.180 |
Why?
|
| Symptom Flare Up | 1 | 2020 | 2 | 0.180 |
Why?
|
| Gels | 1 | 2020 | 14 | 0.180 |
Why?
|
| Long Term Adverse Effects | 1 | 2020 | 1 | 0.180 |
Why?
|
| Behcet Syndrome | 1 | 2020 | 4 | 0.180 |
Why?
|
| Cyclophosphamide | 1 | 2020 | 48 | 0.170 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2020 | 18 | 0.170 |
Why?
|
| Prednisone | 1 | 2020 | 66 | 0.170 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2020 | 79 | 0.170 |
Why?
|
| Internship and Residency | 1 | 2023 | 211 | 0.160 |
Why?
|
| Demography | 1 | 2020 | 72 | 0.160 |
Why?
|
| Immunosuppressive Agents | 1 | 2020 | 120 | 0.160 |
Why?
|
| Diagnosis, Differential | 1 | 2020 | 348 | 0.150 |
Why?
|
| Tissue Fixation | 1 | 2018 | 6 | 0.150 |
Why?
|
| Depressive Disorder | 1 | 2019 | 177 | 0.140 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2020 | 1112 | 0.140 |
Why?
|
| Aftercare | 1 | 2017 | 24 | 0.140 |
Why?
|
| Treatment Outcome | 2 | 2023 | 3485 | 0.140 |
Why?
|
| Longitudinal Studies | 1 | 2021 | 1368 | 0.140 |
Why?
|
| Program Evaluation | 1 | 2017 | 120 | 0.130 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2017 | 49 | 0.130 |
Why?
|
| Disease Management | 1 | 2017 | 102 | 0.130 |
Why?
|
| Patient Readmission | 1 | 2017 | 129 | 0.130 |
Why?
|
| Cognition Disorders | 1 | 2019 | 985 | 0.100 |
Why?
|
| Education, Medical, Graduate | 2 | 2023 | 77 | 0.100 |
Why?
|
| Surveys and Questionnaires | 2 | 2023 | 1144 | 0.070 |
Why?
|
| Rare Diseases | 1 | 2024 | 13 | 0.060 |
Why?
|
| Research Personnel | 1 | 2024 | 19 | 0.060 |
Why?
|
| Mentors | 1 | 2024 | 36 | 0.050 |
Why?
|
| Rituximab | 1 | 2023 | 48 | 0.050 |
Why?
|
| Faculty | 1 | 2023 | 26 | 0.050 |
Why?
|
| Career Choice | 1 | 2022 | 25 | 0.050 |
Why?
|
| Emigrants and Immigrants | 1 | 2022 | 21 | 0.050 |
Why?
|
| Fellowships and Scholarships | 1 | 2022 | 36 | 0.050 |
Why?
|
| Self Report | 1 | 2023 | 223 | 0.050 |
Why?
|
| Pilot Projects | 1 | 2023 | 420 | 0.050 |
Why?
|
| Equipment Design | 1 | 2021 | 138 | 0.050 |
Why?
|
| Clinical Competence | 1 | 2023 | 206 | 0.040 |
Why?
|
| Exercise Test | 1 | 2021 | 118 | 0.040 |
Why?
|
| Infertility | 1 | 2020 | 8 | 0.040 |
Why?
|
| Pandemics | 1 | 2022 | 237 | 0.040 |
Why?
|
| Child | 1 | 2024 | 1295 | 0.040 |
Why?
|
| Retrospective Studies | 2 | 2020 | 3538 | 0.040 |
Why?
|
| Cerebral Angiography | 1 | 2019 | 33 | 0.040 |
Why?
|
| Neurologic Examination | 1 | 2019 | 100 | 0.040 |
Why?
|
| Aged | 2 | 2023 | 8997 | 0.040 |
Why?
|
| United States | 1 | 2022 | 2035 | 0.030 |
Why?
|
| Patient Discharge | 1 | 2017 | 158 | 0.030 |
Why?
|
| Disease Progression | 1 | 2017 | 673 | 0.030 |
Why?
|
| Time Factors | 1 | 2017 | 1433 | 0.030 |
Why?
|
| Risk Factors | 1 | 2017 | 2302 | 0.020 |
Why?
|